Skip to main content
. 2016 Aug 16;7(47):78152–78158. doi: 10.18632/oncotarget.11313

Table 3. Clinical efficacy of afatinib in HER2 mutation NSCLC patients.

Author Number Male/female Efficacy PFS OS
Mazie'res et al.[23] 3 NP SD:2/PR:1 NP NP
 De Grève et al.[24] 3 0/3 SD:2/PR:1 4M 14M
 Current study 4 2/2 SD:3/PD:1 3.5M 17.75M

Abbreviations: NP:not reported; SD: stable disease;PR:partial response;PD:progression disease;M:month